Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. EMPA-REG OUTCOME investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34. https://doi.org/10.1056/NEJMoa1515920.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816.

Article  CAS  PubMed  Google Scholar 

Feng C, Wu M, Chen Z, Yu X, Nie Z, Zhao Y, Bao B. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. 2019;51:655–69. https://doi.org/10.1007/s11255-019-02112-6.

Article  CAS  PubMed  Google Scholar 

Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K, For, on behalf of Primary Care Diabetes Europe. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12:265–83. https://doi.org/10.1016/j.pcd.2018.02.001.

Article  PubMed  Google Scholar 

Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Effects of Sodium-Glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and Meta-analysis of Randomized controlled trials. Sci Rep. 2019;9:13009. https://doi.org/10.1038/s41598-019-49525-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao SD, Zhou L, Tao YY, Yue Y, Wang JX, Shen L, Lu GY, Hang YF. Renal outcomes in asian patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Int J Diabetes Dev Ctries. 2022;42:178–90. https://doi.org/10.1007/s13410-021-00999-5.

Article  CAS  Google Scholar 

Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Clinical implications of estimated glomerular filtration rate Dip following sodium-glucose Cotransporter-2 inhibitor initiation on Cardiovascular and kidney outcomes. J Am Heart Assoc. 2021;10:e020237. https://doi.org/10.1161/JAHA.120.020237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Wada T, Mori-Anai K, Takahashi A, Matsui T, Inagaki M, Iida M, Maruyama K, Tsuda H. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan. J Diabetes Investig. 2022;13:1981–9. https://doi.org/10.1111/jdi.13888.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook. Accessed 9 May 2023.

Kaku K, Kadowaki T, Seino Y, Okamoto T, Shirakawa M, Sato A, O’Neill EA, Engel SS, Kaufman KD. Efficacy and safety of ipragliflozin in japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes Obes Metab. 2021;23:2099–108. https://doi.org/10.1111/dom.14448.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seino Y, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S. Efficacy and safety of luseogliflozin added to insulin therapy in japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr Med Res Opin. 2018;34:981–94. https://doi.org/10.1080/03007995.2018.1441816.

Article  CAS  PubMed  Google Scholar 

Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y. Influence of renal function on the 52-Week efficacy and safety of the Sodium glucose cotransporter 2 inhibitor luseogliflozin in japanese patients with type 2 diabetes Mellitus. Clin Ther. 2016;38:66–88e20. https://doi.org/10.1016/j.clinthera.2015.10.025.

Article  CAS  PubMed  Google Scholar 

Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A, Ueyama E. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152–60. https://doi.org/10.1111/dom.12403.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kashiwagi A, Akiyama N, Shiga T, et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol Int. 2015;6:125–38. https://doi.org/10.1007/s13340-014-0184-9.

Article  Google Scholar 

Kashiwagi A, Shiga T, Akiyama N, et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int. 2015;6:104–16. https://doi.org/10.1007/s13340-014-0182-y.

Article  Google Scholar 

Kashiwagi A, Kazuta K, Takinami, et al. Ipragliflozin improves glycemic control in japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetol Int. 2015;6:8–18. https://doi.org/10.1007/s13340-014-0164-0.

Article  Google Scholar 

Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmacother. 2014;15:1501–15. https://doi.org/10.1517/14656566.2014.935764.

Article  CAS  PubMed  Google Scholar 

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D, Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65. https://doi.org/10.1186/1475-2840-13-65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of luseogliflozin in japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30:1231–44. https://doi.org/10.1185/03007995.2014.909390.

Article  CAS  PubMed  Google Scholar 

Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin monotherapy in japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30:1219–30. https://doi.org/10.1185/03007995.2014.901943.

Article  CAS  PubMed  Google Scholar 

Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30:1245–55. https://doi.org/10.1185/03007995.2014.912983.

Article  CAS  PubMed  Google Scholar 

Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99:750–62. https://doi.org/10.1016/j.kint.2020.10.031.

Article  CAS  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. EMPA-REG OUTCOME investigators. Empagliflozin, Cardiovascular Outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720.

Article  CAS  PubMed  Google Scholar 

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;2:1237–50. https://doi.org/10.1111/dom.13648.

Article  CAS  Google Scholar 

Takeuchi M, Ogura M, Minoura T, Inagaki N, Kawakami K. Comparative effectiveness of sodium-glucose Cotransporter-2 inhibitors Versus other classes of glucose-lowering medications on renal outcome in type 2 diabetes. Mayo Clin Proc. 2020;95:265–73. https://doi.org/10.1016/j.mayocp.2019.12.004.

Article  CAS  PubMed  Google Scholar 

Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41. https://doi.org/10.1291/hypres.31.433.

Article  PubMed  Google Scholar 

Kohagura K, Yamasaki H, Takano H, Ohya Y, Seino Y. Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in japanese patients with type 2 diabetes. Hypertens Res. 2020;43:876–83. https://doi.org/10.1038/s41440-020-0426-0.

Article